share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  07/03 16:16
Moomoo AI 已提取核心訊息
On July 3, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced a strategic shift to focus on the clinical development of vebreltinib for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations. This decision is aimed at addressing a significant unmet medical need. The company's SPARTA Phase 2 clinical trial will continue enrolling NSCLC patients with Met amplification and follow current patients with solid tumors with MET alterations. Leadership changes were also announced, with co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., transitioning to consulting roles in August. These changes are part of a cost reduction plan that is expected to reduce ongoing operating expenses by over 50% and extend the company's capital runway into the third quarter of 2025. Vebreltinib, a c-MET inhibitor, has shown promise in preclinical models and has received conditional approval from China's NMPA, though it is not yet approved elsewhere.
On July 3, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced a strategic shift to focus on the clinical development of vebreltinib for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations. This decision is aimed at addressing a significant unmet medical need. The company's SPARTA Phase 2 clinical trial will continue enrolling NSCLC patients with Met amplification and follow current patients with solid tumors with MET alterations. Leadership changes were also announced, with co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., transitioning to consulting roles in August. These changes are part of a cost reduction plan that is expected to reduce ongoing operating expenses by over 50% and extend the company's capital runway into the third quarter of 2025. Vebreltinib, a c-MET inhibitor, has shown promise in preclinical models and has received conditional approval from China's NMPA, though it is not yet approved elsewhere.
2024年7月3日，普洛米克斯公司，一家後期臨床生物製藥公司，宣佈戰略轉移，專注於發展針對非小細胞肺癌（NSCLC）患有Met擴增突變的vebreltinib的臨床。此決定旨在解決重大的醫學需求。公司的SPARTA第二期臨床試驗將繼續招募Met擴增的NSCLC患者，並跟進當前患有固體腫瘤的Met基因改變患者的情況。領導層的變動也宣佈，聯合創始人兼總裁Sanjeev Redkar博士和首席醫療官餘佳潔醫生將在8月過渡到諮詢角色。這些變化是成本削減計劃的一部分，預計將減少超過50%的持續營業費用，將公司的資本補給延長到2025年第三季度。vebreltinib作爲c-MET抑制劑，已在臨床前模型中顯示出潛力，並獲得中國國家藥品監督管理局的條件批准，但尚未在其他國家獲得批准。
2024年7月3日，普洛米克斯公司，一家後期臨床生物製藥公司，宣佈戰略轉移，專注於發展針對非小細胞肺癌（NSCLC）患有Met擴增突變的vebreltinib的臨床。此決定旨在解決重大的醫學需求。公司的SPARTA第二期臨床試驗將繼續招募Met擴增的NSCLC患者，並跟進當前患有固體腫瘤的Met基因改變患者的情況。領導層的變動也宣佈，聯合創始人兼總裁Sanjeev Redkar博士和首席醫療官餘佳潔醫生將在8月過渡到諮詢角色。這些變化是成本削減計劃的一部分，預計將減少超過50%的持續營業費用，將公司的資本補給延長到2025年第三季度。vebreltinib作爲c-MET抑制劑，已在臨床前模型中顯示出潛力，並獲得中國國家藥品監督管理局的條件批准，但尚未在其他國家獲得批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息